Warm Autoimmune hemolytic anemia (WAIHA) Market to Witness Transformational Growth Opportunities by 2036 - DelveInsight

DelveInsight's "Warm Autoimmune hemolytic anemia Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Warm Autoimmune hemolytic anemia, historical and forecasted epidemiology as well as the Warm Autoimmune hemolytic anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Warm Autoimmune hemolytic anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Warm Autoimmune hemolytic anemia Market Forecast
https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Warm Autoimmune hemolytic anemia Market Report:
• The warm autoimmune hemolytic anemia (wAIHA) market size was valued at approximately USD 600 million in 2025 and is projected to reach nearly USD 2.4 billion by 2036, growing at a CAGR of 14.4% during 2026-2036.
• In February 2026, the US FDA awarded Breakthrough Therapy Designation (BTD) to WAYRILZ (rilzabrutinib) for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA). In addition, Japan's Ministry of Health, Labour and Welfare granted rilzabrutinib Orphan Drug Designation (ODD) for the same indication.
• In February 2026, Johnson & Johnson filed a supplemental Biologics License Application (sBLA) with the U.S. FDA for IMAAVY, aiming to secure approval as the first treatment specifically indicated for warm autoimmune hemolytic anemia. The submission is backed by Phase II/III ENERGY trial results demonstrating rapid and sustained improvements in hemoglobin levels.
• In February 2026, Sanofi announced that the U.S. FDA has granted Breakthrough Therapy designation to Wayrilz (rilzabrutinib) for the treatment of warm autoimmune hemolytic anemia (wAIHA). Rilzabrutinib is a novel oral and reversible Bruton's tyrosine kinase (BTK) inhibitor developed for this rare autoimmune condition characterized by the destruction of red blood cells.
• In February 2025, Zenas BioPharma, Inc. (Nasdaq: ZBIO), a global clinical-stage biopharmaceutical company focused on autoimmune disease therapies, is conducting the Phase 2 SApHiAre trial an international, multicenter, open-label study featuring a safety and dose confirmation run-in period (SRP) to assess obexelimab in patients with warm Autoimmune Hemolytic Anemia (wAIHA). Obexelimab demonstrated clinical proof-of-mechanism by improving hemoglobin and red blood cell counts, while reducing LDH and total bilirubin levels. The treatment was also well tolerated during the SRP phase.
• The emerging pipeline is shifting the field toward mechanism-driven immune modulation, with late-stage candidates targeting key pathways involved in IgG-mediated hemolysis. Notable programs include IMAAVY (nipocalimab) from Johnson & Johnson, WAYRILZ (rilzabrutinib) from Sanofi, and ianalumab from Novartis.
• Overall, the emergence of targeted therapies and increasing recognition of disease burden are expected to drive steady growth in the 7MM wAIHA market from 2022-2036, with significant commercial potential for emerging pipeline treatments.
• In 2025, the United States accounted for the largest share of the wAIHA market within the 7MM, representing nearly 60% of the total market value.
• In 2036, among all the therapies for wAIHA, the highest revenue is estimated to be generated by IMAAVY, in the United States.
• The entry of late-stage candidates such as IMAAVY, Ianalumab, and WAYRILZ is expected to intensify competition in the second half of the forecast period.
• In 2025, the total number of diagnosed prevalent cases of AIHA across the 7MM was estimated at approximately 120,000.
• In the United States, primary wAIHA accounted for around 20,500 diagnosed prevalent cases in 2025, while secondary wAIHA comprised approximately 22,200 cases.
• In 2025, females accounted for about 60% of diagnosed prevalent wAIHA cases across EU4 and the UK, while males represented around 40%.
• In 2025, across EU4 and the UK, the ≥65 age group accounted for around 55% of wAIHA cases, followed by the 45-64 age group at approximately 25%.
• In 2025, in Japan, severe wAIHA accounted for around 420 cases, while non-severe cases were estimated at approximately 600.
• Key Warm Autoimmune hemolytic anemia Companies: Zenas BioPharma, Novartis, MorphoSys, Alpine Immune Sciences, Rigel Pharma, Incyte Corp, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharma, Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others
• Key Warm Autoimmune hemolytic anemia Therapies: Obexelimab (ZB012), Ianalumab, Povetacicept, Fostamatinib, Parsaclisib, Rilzabrutinib, Nipocalimab, M281, ANX005, APL-2, Fostamatinib disodium, HMPL-523(300mg PO QD), and others
• The Warm Autoimmune hemolytic anemia epidemiology based on gender analyzed that in case of Warm Autoimmune hemolytic anemia, gender ratio revealed preponderance of the female gender over the male counterpart
• The Warm Autoimmune hemolytic anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Warm Autoimmune hemolytic anemia pipeline products will significantly revolutionize the Warm Autoimmune hemolytic anemia market dynamics.

Warm Autoimmune hemolytic anemia Overview
Warm Autoimmune Hemolytic Anemia (WAIHA) is a condition where the immune system mistakenly attacks and destroys its own red blood cells at normal body temperatures. This leads to anemia, a shortage of red blood cells, causing symptoms like fatigue, pale skin, jaundice, and an increased heart rate. The exact cause of WAIHA is often unknown but can be linked to other conditions, such as autoimmune disorders, infections, or certain medications. Treatment typically involves managing the underlying cause, medications to suppress the immune system, and in some cases, blood transfusions.

Get a Free sample for the Warm Autoimmune hemolytic anemia Market Report:
https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Warm Autoimmune hemolytic anemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Warm Autoimmune hemolytic anemia Epidemiology Segmentation:
The Warm Autoimmune hemolytic anemia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalence of Warm Autoimmune hemolytic anemia
• Prevalent Cases of Warm Autoimmune hemolytic anemia by severity
• Gender-specific Prevalence of Warm Autoimmune hemolytic anemia
• Diagnosed Cases of Episodic and Chronic Warm Autoimmune hemolytic anemia

Download the report to understand which factors are driving Warm Autoimmune hemolytic anemia epidemiology trends @ Warm Autoimmune hemolytic anemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Warm Autoimmune hemolytic anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Warm Autoimmune hemolytic anemia market or expected to get launched during the study period. The analysis covers Warm Autoimmune hemolytic anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Warm Autoimmune hemolytic anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Warm Autoimmune hemolytic anemia Therapies and Key Companies
• Obexelimab (ZB012): Zenas BioPharma
• Ianalumab (Novartis/MorphoSys)
• Povetacicept (Alpine Immune Sciences)
• Fostamatinib: Rigel Pharmaceuticals
• Parsaclisib: Incyte Corporation
• Rilzabrutinib: Sanofi
• Nipocalimab: Johnson & Johnson
• M281: Janssen Research & Development
• ANX005: Annexon, Inc.
• APL-2: Apellis Pharmaceuticals, Inc.
• Fostamatinib disodium: Rigel Pharmaceuticals
• HMPL-523(300mg PO QD): Hutchison Medipharma Limited

Discover more about therapies set to grab major Warm Autoimmune hemolytic anemia market share @ Warm Autoimmune hemolytic anemia Treatment Market
https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Warm Autoimmune hemolytic anemia Market Drivers
• Increasing patient population
• Advancement in research and development
• Improved clinical trials
• Patient assistance programs
• New therapeutic agents

Warm Autoimmune hemolytic anemia Market Barriers
• Increasing refractory cases
• Associated co-morbidities
• Unavailability of better treatment options
• Therapy failure
• Lack of disease understanding
• Unavailability of curative treatment

Scope of the Warm Autoimmune hemolytic anemia Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Warm Autoimmune hemolytic anemia Companies: Zenas BioPharma, Novartis, MorphoSys, Alpine Immune Sciences, Rigel Pharma, Incyte Corp, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharma, Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others
• Key Warm Autoimmune hemolytic anemia Therapies: Obexelimab (ZB012), Ianalumab, Povetacicept, Fostamatinib, Parsaclisib, Rilzabrutinib, Nipocalimab, M281, ANX005, APL-2, Fostamatinib disodium, HMPL-523(300mg PO QD), and others
• Warm Autoimmune hemolytic anemia Therapeutic Assessment: Warm Autoimmune hemolytic anemia current marketed and Warm Autoimmune hemolytic anemia emerging therapies
• Warm Autoimmune hemolytic anemia Market Dynamics: Warm Autoimmune hemolytic anemia market drivers and Warm Autoimmune hemolytic anemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Warm Autoimmune hemolytic anemia Unmet Needs, KOL's views, Analyst's views, Warm Autoimmune hemolytic anemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.